Osimertinib
Brand: Tagrisso (global)
Anticancer
EGFR TKI (3rd gen)
Pharmacokinetics
| Half-life | 48 hours |
| Tmax | 6 h |
| Bioavailability | 70 % (approx) |
| Protein Binding | 95 % |
| Volume of Distribution | 918 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Effective in T790M; high CNS penetration. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
QT prolongation, ILD/pneumonitis, diarrhea, rash
Contraindications:
Baseline QT prolongation
Precautions:
ECG monitoring if cardiac risk; hold therapy if ILD suspected
half life ≈ 48 hours
dose standard = 80 mg per day